

**Table S1** PCR primer sequences used to distinguish between the CYP3A5\*3 and CYP3A4\*1G genotypes.

<b>Gene</b>	<b>Primer</b>
CYP3A5*3 (rs776746)	Forward: 5' TAATCCATACCCCTAGTTGTACGAC 3' Reverse: 5' TACCTGCCTTCAATTTCAC TG 3'
CYP3A4*1G (rs2242480)	Forward: 5' CTTTCAGAGCCTCCTACATAGAG 3' Reverse: 5' GATGCCCTACATTGATCTGATTAC 3'

**Table S2** Pharmacokinetic parameters of tacrolimus stratified by CYP3A4 genotype .

Parameter	All (CV%) n=14	CYP3A4*1/*1 (CV%) n=9	Non-CYP3A4*1/*1(CV%) n=5
C <sub>max</sub> (ng/mL)	14.55±1.87 (69.08)	17.84±1.68 (55.77)	10.08±1.98 (76.94)
C <sub>max</sub> /D(ng/mL)	12.70±2.29 (99.66)	17.06±2.29 (99.58)	7.46±1.75 (60.85)
C <sub>min</sub> (ng/mL)	5.58±2.34 (103.17)	7.82±2.15 (88.96)	3.03±1.98 (77.34)*
C <sub>min</sub> /D(ng/mL)	4.87±2.94 (148.55)	7.48±2.88 (143.94)	2.25±1.85 (67.96)*
T <sub>max</sub> (h)	2.00 (0.50-6.00)	2.00 (0.50-6.00)	2.00 (1.00-4.00)
CL/F(L/h)	9.95±2.60 (121.94)	6.97±2.55 (118.70)	18.85±1.89 (70.97)
AUC <sub>0-12h</sub> (ng·h/mL)	115.23±2.03 (80.50)	150.02±1.89 (70.72)	71.67±1.84 (67.36)
AUC <sub>0-12h</sub> /D(ng·h/mL)	100.54±2.60 (121.94)	143.41±2.55 (118.70)	53.05±1.89 (70.97)

Values are expressed as the geometric mean ± geometric standard deviation or median (minimum-maximum). CV%: geometric coefficient of variation; C<sub>max</sub>: maximum concentration; C<sub>max</sub>/D: C<sub>max</sub> of dose normalised to 1mg; C<sub>min</sub>: minimum concentration; C<sub>min</sub>/D: C<sub>min</sub> of dose normalised to 1mg; T<sub>max</sub>: time at which C<sub>max</sub> occurred; CL/F: apparent clearance; AUC<sub>0-12h</sub> : AUC within 12-hour dosing interval; AUC<sub>0-12h</sub>/D: AUC<sub>0-12h</sub> of dose normalised to 1mg.

\*p≤0.05 (ANOVA) Non- CYP3A4\*1/\*1 carriers versus CYP3A4\*1/\*1 carriers